---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-331369"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2021-11-16T23:59:59+00:00"
generated_at: "2026-06-28T07:47:45.626995+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roche terminates license agreement for AT-527 with Atea; effective Feb 10, 2022

## Summary
- Roche sent termination notice on Nov 12, 2021; license ends Feb 10, 2022.
- Agreement covered ex-U.S. rights to develop and commercialize AT-527.
- No early termination penalties will be incurred by Atea.
- Atea retains full rights to AT-527 outside the terminated pact.

## SEC filing metadata
- accession: 0001193125-21-331369
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2021-11-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312521331369/0001193125-21-331369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312521331369/d368899d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-331369
- JSON: https://secwatch.observer/filing/0001193125-21-331369.json
- Plain text: https://secwatch.observer/filing/0001193125-21-331369.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.